Objectives Decision makers use models to assist in evaluating the cost-effectiveness of
pharmacologic stroke prevention in atrial fibrillation (SPAF). Study Design and Setting We …

Background Previous investigations into the cost effectiveness of direct oral anticoagulants
only considered individual stroke risk but not bleed risk even though bleeding is an …

Background and Purpose—In controlled trials, anticoagulation with warfarin reduces stroke
risk by nearly two thirds, but the benefit has been less pronounced in clinical practice. This …

Objective: To construct a semi-Markov model to compare health outcomes and medical
costs associated with warfarin and a second anticoagulant over 1-and 5-year periods …

Background Anticoagulation therapy with warfarin is widely considered the standard of care
for stoke prophylaxis in patients with atrial fibrillation who are at high risk of stroke …

The aim of this study was to summarize healthcare costs incurred by patients with atrial
fibrillation (AF) who developed ischaemic stroke, explore factors associated with increased …

A major cause of morbidity and mortality among patients with atrial fibrillation (AF) relates to
the increased risk of stroke. The burden of illness that AF imparts on stroke is likely to …

Background Updated treatment guidelines for atrial fibrillation (AF) have been released by
the National Institute for Health and Care Excellence (NICE) in the UK, and highlight a …

Background Oral anticoagulation therapy reduces the risk of ischemic stroke in patients with
atrial fibrillation (AF). However, more data on the costs of stroke in patients with AF are …

Background Vitamin K antagonists, such as warfarin, are standard treatments for stroke
prophylaxis in patients with atrial fibrillation. Patient outcomes depend on quality of warfarin …